Flag of the European Union EU Clinical Trials Register Help

Clinical trials for sanofi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,200 result(s) found for: sanofi. Displaying page 31 of 110.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    EudraCT Number: 2006-004129-27 Sponsor Protocol Number: X06-MMRV-302 Start Date*: 2006-12-13
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (...
    Medical condition: The study will involve healthy children.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002259-14 Sponsor Protocol Number: TRG12-05 Start Date*: 2013-11-27
    Sponsor Name:University of Oxford
    Full Title: The effect of lixisenatide in type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004936-31 Sponsor Protocol Number: ICADTSIII Start Date*: 2014-05-28
    Sponsor Name:Ministry of Infrastructure and the Environment
    Full Title: Establish limits for fitness to drive with prolonged use of ICADTS class III medication
    Medical condition: Depression, anxiety, sleep disorders
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000749-30 Sponsor Protocol Number: MET51 Start Date*: 2016-11-30
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001518-26 Sponsor Protocol Number: DFI10569 Start Date*: 2009-03-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Efficacy and safety of oral ataciguat (HMR1766) 200 mg administered once daily for 28 days on pain reduction in patients with Neuropathic Pain. A randomized, double-blind, placebo-controlled, cross...
    Medical condition: The proposed study is planned to demonstrate that ataciguat 200 mg/day could be effective in reducing neuropathic pain with a good safety profile
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002063-14 Sponsor Protocol Number: GEMCAD-1402 Start Date*: 2014-10-23
    Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo)
    Full Title: Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial
    Medical condition: Patients with high risk locally advanced rectal carcinoma (defined by Magnetic Resonance Imaging [MRI]), who are candidates for multimodality treatment.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004461-41 Sponsor Protocol Number: MET59 Start Date*: 2020-02-14
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006521-30 Sponsor Protocol Number: LTS10036 Start Date*: 2007-09-26
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC449...
    Medical condition: Cirrhotic ascites
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003445 Ascites LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Completed) BE (Completed) SE (Completed) DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003134-14 Sponsor Protocol Number: PDY6045 Start Date*: 2007-06-04
    Sponsor Name:Sanofi-aventis U.S. Inc.
    Full Title: A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006473-24 Sponsor Protocol Number: EFC10073 Start Date*: 2007-07-03
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combinati...
    Medical condition: high risk localized breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002844-42 Sponsor Protocol Number: EFC13403 Start Date*: 2015-02-11
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine
    Medical condition: Type2-Diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015066-61 Sponsor Protocol Number: ACT10776 Start Date*: 2009-12-11
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.
    Medical condition: Diabetic peripheral neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-001328-77 Sponsor Protocol Number: DRI13940 Start Date*: 2017-02-07
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients with Type 2 Diabetes Mellitus
    Medical condition: Nutritional and metabolic diseases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003070-31 Sponsor Protocol Number: VAN00002 Start Date*: 2022-01-24
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10076061 Meningococcal immunisation PT
    Population Age: Infants and toddlers, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-004148-39 Sponsor Protocol Number: TED15138 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An open-label, first-in-human, dose escalation study of SAR440234 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-ce...
    Medical condition: Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024288 Leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004906-32 Sponsor Protocol Number: EFC15166 Start Date*: 2017-12-21
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Se...
    Medical condition: Type 2 diabetes mellitus Chronic kidney disease stage 4
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004889-26 Sponsor Protocol Number: EFC14837 Start Date*: 2017-09-01
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Mo...
    Medical condition: Type 2 diabetes mellitus Chronic kidney disease stage 3
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.0 100000070575 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-003542-36 Sponsor Protocol Number: LPS16763 Start Date*: 2021-01-19
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A multi-center, exploratory study to assess dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004520-30 Sponsor Protocol Number: MET52 Start Date*: 2018-07-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and safety study of an investigational quadrivalent meningococcal conjugate vaccine in infants and toddlers when administered using a 1+1 schedule in a National Immunization Schedule...
    Medical condition: Active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003756-33 Sponsor Protocol Number: EFC16720 Start Date*: 2021-03-25
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel-group study of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1-antihi...
    Medical condition: Cold Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:24:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA